Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00029029
Recruitment Status : Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : June 6, 2018
Information provided by (Responsible Party):
Mayo Clinic

January 4, 2002
January 27, 2003
June 6, 2018
October 13, 2000
October 24, 2002   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00029029 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells and may help to relieve pain caused by bone metastases.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in relieving pain in patients who have bone metastases.


  • Determine the efficacy of radiofrequency ablation, in terms of pain relief at 4 weeks, in patients with painful bone metastases.
  • Determine the safety of this regimen in these patients.
  • Compare the change in pain interference with daily life and analgesic use at 4 weeks vs baseline in patients treated with this regimen.
  • Determine the time to recurrence of worst pain in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive radiofrequency ablation (RFA) to targeted tumor(s) on day 0 (multiple tumors may receive ablation in multiple sessions). Patients who achieve a reduction in worst pain of at least 2 points within 4-8 weeks but experience recurring pain at the RFA site or are diagnosed with a new painful lesion within 4-24 weeks receive 1 additional treatment to the recurring or new site.

Pain (using the Brief Pain Inventory scale of 0-10), analgesic use, and quality of life are assessed at baseline, on day 1, weekly for 4 weeks, and then every 2 weeks for 20 weeks.

Patients are followed for 6 months beyond the last RFA treatment.

PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.

Phase 2
Primary Purpose: Supportive Care
  • Metastatic Cancer
  • Pain
  • Procedure: pain therapy
  • Procedure: radiofrequency ablation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
Not Provided
October 24, 2020
October 24, 2002   (Final data collection date for primary outcome measure)


  • Histologically or cytologically confirmed bone metastases
  • Pain refractory to non-opioid analgesic medication and radiotherapy OR
  • Patient is considered a poor candidate for opioid analgesics or radiotherapy
  • Initial worst pain score within the past 24 hours at least 4 on a scale of 0-10
  • Tumors deemed accessible for radiofrequency ablation
  • No evidence of impending fracture in weight-bearing bones (more than 50% loss of cortical bone)
  • Tumors must be more than 1 cm from critical structures including:

    • Spinal cord, brain, or other critical nerve structures
    • Large abdominal vessel (e.g., aorta or inferior vena cava)
    • Bowel or bladder



  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • More than 2 months


  • Platelet count at least 75,000/mm3


  • INR less than 1.5


  • Not specified


  • Not pregnant or nursing
  • Negative pregnancy test


Biologic therapy:

  • Not specified


  • At least 3 weeks since prior chemotherapy

Endocrine therapy:

  • Not specified


  • At least 3 weeks since prior radiotherapy


  • Not specified


  • At least 3 days since prior aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs
  • No concurrent anticoagulants
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Mayo Clinic
Mayo Clinic
Not Provided
Study Chair: J. William Charboneau, MD Mayo Clinic
Mayo Clinic
June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP